Company: ABBV
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001551152-25-000040
Chunk: 7

Company: AbbVie Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 2
Chunk 7
---
International30 4 >100.0 %>100.0 %51 7 >100.0 %>100.0 %Total$267 $150 77.5 %76.9 %$460 $281 63.6 %63.6 %VyalevUnited States$22 $— n/mn/m$28 $— n/mn/mInternational76 18 >100.0 %>100.0 %133 27 >100.0 %>100.0 %Total$98 $18 >100.0 %>100.0 %$161 $27 >100.0 %>100.0 %DuodopaUnited States$20 $23 (13.6)%(13.6)%$40 $48 (16.6)%(16.6)%International77 90 (13.7)%(16.3)%153 180 (14.9)%(14.0)%Total$97 $113 (13.7)%(15.7)%$193 $228 (15.2)%(14.5)%Other NeuroscienceUnited States$51 $57 (11.4)%(11.4)%$106 $118 (10.4)%(10.4)%International4 5 (23.3)%(21.3)%8 9 (12.7)%(8.1)%Total$55 $62 (12.3)%(12.2)%$114 $127 (10.5)%(10.2)%OncologyImbruvicaUnited States$543 $595 (8.9)%(8.9)%$1,072 $1,205 (11.1)%(11.1)%Collaboration revenues211 238 (11.2)%(11.2)%420 466 (9.7)%(9.7)%Total$754 $833 (9.5)%(9.5)%$1,492 $1,671 (10.7)%(10.7)%VenclextaUnited States$321 $300 7.4 %7.4 %$633 $581 9.1 %9.1 %International370 337 9.5 %9.1 %723 670